Detalhe da pesquisa
1.
N1-Benzoylated 5-(4-pyridinyl)indazole-based kinase inhibitors: Attaining haspin and Clk4 selectivity via modulation of the benzoyl substituents.
Arch Pharm (Weinheim)
; 357(6): e2400020, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38478964